21.01

6.16% 1.2079

Elanco Animal Health Inc (ELAN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$19.80

Aprire:

$20.12

Volume 24 ore:

5.00M

Relative Volume:

0.89

Capitalizzazione di mercato:

$10.49B

Reddito:

$4.72B

Utile/perdita netta:

$-232.00M

Rapporto P/E:

-45.05

EPS:

-0.4663

Flusso di cassa netto:

$284.00M

1 W Prestazione:

-3.58%

1M Prestazione:

-11.23%

6M Prestazione:

-1.04%

1 anno Prestazione:

+60.70%

Intervallo 1D:

$19.85

$21.11

Intervallo di 1 settimana:

$19.40

$22.17

Portata 52W:

$12.40

$27.72

Elanco Animal Health Inc Stock (ELAN) Company Profile

Nome

Elanco Animal Health Inc

Settore

Healthcare (1106)

Industria

Drug Manufacturers - Specialty & Generic (85)

Telefono

877-352-6261

Indirizzo

450 ELANCO CIRCLE, INDIANAPOLIS

Dipendente

9,900

Cinguettio

@Elanco

Prossima data di guadagno

2026-05-06

Ultimi documenti SEC

ELAN's Discussions on Twitter

Compare ELAN vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ELAN Elanco Animal Health Inc	21.00	9.95B	4.72B	-232.00M	284.00M	-0.4663
TAK Takeda Pharmaceutical Co Adr	16.70	52.36B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.295	40.62B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.38	39.63B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	80.33	32.58B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	565.75	24.07B	3.17B	1.29B	1.01B	27.09

Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-15	Iniziato	Citigroup	Buy
2026-01-22	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-12-09	Iniziato	Barclays	Overweight
2025-11-21	Iniziato	KeyBanc Capital Markets	Overweight
2025-11-19	Aggiornamento	Argus	Hold → Buy
2025-10-07	Aggiornamento	JP Morgan	Neutral → Overweight
2025-07-17	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-06-26	Aggiornamento	William Blair	Mkt Perform → Outperform
2024-12-09	Iniziato	UBS	Buy
2024-12-02	Iniziato	Leerink Partners	Market Perform
2024-09-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2024-01-05	Aggiornamento	Stifel	Hold → Buy
2023-12-19	Iniziato	Jefferies	Buy
2023-12-15	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2023-12-07	Iniziato	Exane BNP Paribas	Outperform
2023-04-20	Aggiornamento	Barclays	Equal Weight → Overweight
2022-08-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-08-16	Downgrade	JP Morgan	Overweight → Neutral
2022-07-21	Downgrade	Goldman	Buy → Sell
2022-07-12	Iniziato	Piper Sandler	Neutral
2021-11-18	Iniziato	Morgan Stanley	Overweight
2021-10-28	Downgrade	Stifel	Buy → Hold
2021-08-05	Ripresa	Credit Suisse	Outperform
2021-06-15	Aggiornamento	Cleveland Research	Underperform → Neutral
2021-05-11	Aggiornamento	Barclays	Underweight → Equal Weight
2021-05-11	Aggiornamento	Gabelli & Co	Hold → Buy
2021-04-15	Iniziato	Stifel	Buy
2021-03-22	Downgrade	Gabelli & Co	Buy → Hold
2021-02-26	Aggiornamento	Credit Suisse	Neutral → Outperform
2020-12-09	Downgrade	Argus	Buy → Hold
2020-11-09	Downgrade	Barclays	Overweight → Underweight
2020-08-20	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-08-13	Ripresa	Credit Suisse	Neutral
2020-08-04	Ripresa	Goldman	Buy
2020-07-27	Downgrade	Cleveland Research	Neutral → Underperform
2020-04-02	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-01-10	Iniziato	Raymond James	Mkt Perform
2019-12-19	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-11-07	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-09-23	Iniziato	Barclays	Overweight
2019-08-26	Downgrade	BofA/Merrill	Buy → Neutral
2019-08-15	Aggiornamento	UBS	Sell → Neutral
2019-05-23	Iniziato	Guggenheim	Neutral
2019-03-18	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-03-13	Ripresa	Morgan Stanley	Equal-Weight
2019-02-12	Iniziato	William Blair	Mkt Perform
2019-01-23	Iniziato	UBS	Sell
2019-01-15	Iniziato	Argus	Buy
2018-10-15	Iniziato	Morgan Stanley	Equal-Weight

Mostra tutto

Elanco Animal Health Inc Borsa (ELAN) Ultime notizie

May 19, 2026

Elanco CEO Jeffrey Simmons buys $99,842 in company stock - Investing.com

May 19, 2026

Elanco EVP Rajeev Modi buys $99,938 of company stock - Investing.com

May 19, 2026

Elanco (NYSE: ELAN) officer Modi buys shares and receives deferred stock units - Stock Titan

May 19, 2026

Elanco (NYSE: ELAN) CEO adds shares and receives deferred units - Stock Titan

May 19, 2026

Elanco (NYSE: ELAN) CFO receives grant of deferred stock units as compensation - Stock Titan

May 19, 2026

Elanco Animal Health Launches Canine Dermatitis Drug Befrena - Moomoo

May 19, 2026

May 18, 2026

Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets - Investing.com India

May 18, 2026

Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets By Investing.com - Investing.com South Africa

May 18, 2026

Elanco (ELAN) Launches New Canine Allergy Treatment Befrena - GuruFocus

May 18, 2026

Elanco launches canine dermatitis treatment Befrena in U.S. By Investing.com - Investing.com Canada

May 18, 2026

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market - PR Newswire

May 18, 2026

Elanco Animal Health (ELAN) Stock Report: A Healthcare Stock with Nearly 50% Upside Potential - DirectorsTalk Interviews

May 18, 2026

May 17, 2026

Elanco Q1 2026 Earnings: Revenue $1.37B, EPS $0.40, Guidance RaisedNews and Statistics - IndexBox

May 17, 2026

May 16, 2026

5 Insightful Analyst Questions From Elanco’s Q1 Earnings Call - Yahoo Finance

May 16, 2026

May 15, 2026